1. Home
  2. MLKN vs PHVS Comparison

MLKN vs PHVS Comparison

Compare MLKN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLKN
  • PHVS
  • Stock Information
  • Founded
  • MLKN 1905
  • PHVS 2015
  • Country
  • MLKN United States
  • PHVS Switzerland
  • Employees
  • MLKN N/A
  • PHVS N/A
  • Industry
  • MLKN Office Equipment/Supplies/Services
  • PHVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MLKN Consumer Discretionary
  • PHVS Health Care
  • Exchange
  • MLKN Nasdaq
  • PHVS Nasdaq
  • Market Cap
  • MLKN 1.2B
  • PHVS 1.3B
  • IPO Year
  • MLKN N/A
  • PHVS 2021
  • Fundamental
  • Price
  • MLKN $21.40
  • PHVS $24.03
  • Analyst Decision
  • MLKN
  • PHVS Buy
  • Analyst Count
  • MLKN 0
  • PHVS 6
  • Target Price
  • MLKN N/A
  • PHVS $36.67
  • AVG Volume (30 Days)
  • MLKN 365.8K
  • PHVS 109.7K
  • Earning Date
  • MLKN 09-23-2025
  • PHVS 08-12-2025
  • Dividend Yield
  • MLKN 3.44%
  • PHVS N/A
  • EPS Growth
  • MLKN N/A
  • PHVS N/A
  • EPS
  • MLKN N/A
  • PHVS N/A
  • Revenue
  • MLKN $3,669,900,000.00
  • PHVS N/A
  • Revenue This Year
  • MLKN $4.74
  • PHVS N/A
  • Revenue Next Year
  • MLKN $3.64
  • PHVS N/A
  • P/E Ratio
  • MLKN N/A
  • PHVS N/A
  • Revenue Growth
  • MLKN 1.14
  • PHVS N/A
  • 52 Week Low
  • MLKN $15.25
  • PHVS $11.51
  • 52 Week High
  • MLKN $30.56
  • PHVS $26.33
  • Technical
  • Relative Strength Index (RSI)
  • MLKN 57.66
  • PHVS 65.92
  • Support Level
  • MLKN $21.29
  • PHVS $21.56
  • Resistance Level
  • MLKN $22.17
  • PHVS $24.96
  • Average True Range (ATR)
  • MLKN 0.67
  • PHVS 1.25
  • MACD
  • MLKN 0.04
  • PHVS 0.19
  • Stochastic Oscillator
  • MLKN 69.92
  • PHVS 86.20

About MLKN MillerKnoll Inc.

MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: